Histone deacetylase (HDAC) inhibitors are amongst the newer therapies being introduced in
refractory, relapsed, and resistant disease. These agents are mechanism-based and their
use is targeted to the diseased cell or tissue. HDACs are key enzymes in the regulation of
gene expression. They maintain a dynamic equilibrium in the acetylation state of highly
conserved lysine residues on histones by which they regulate chromatin remodeling and
gene expression. Changes in growth and differentiation leading to malignancy appear to …

Abstract Background Myelodysplastic Syndrome (MDS) represents a heterogeneous group
of diseases with clonal proliferation, bone marrow failure and increase risk of progression to
acute leukemia. Histone deacetylase inhibitors (HDACi) modulate the epigenetics of cancer
cells to promote differentiation and programmed cell death. Our aim is to study the efficacy
and safety of HDACi in patients with MDS/acute myeloid leukemia (AML). HDACi can be a
safer alternative in patients with high risk MDS who are not eligible for stem cell …